226 related articles for article (PubMed ID: 16272333)
1. Absence of thrombin-activatable fibrinolysis inhibitor protects against sepsis-induced liver injury in mice.
Renckens R; Roelofs JJ; ter Horst SA; van 't Veer C; Havik SR; Florquin S; Wagenaar GT; Meijers JC; van der Poll T
J Immunol; 2005 Nov; 175(10):6764-71. PubMed ID: 16272333
[TBL] [Abstract][Full Text] [Related]
2. Thrombin-activatable fibrinolysis inhibitor influences disease severity in humans and mice with pneumococcal meningitis.
Mook-Kanamori BB; Valls Serón M; Geldhoff M; Havik SR; van der Ende A; Baas F; van der Poll T; Meijers JC; P Morgan B; Brouwer MC; van de Beek D
J Thromb Haemost; 2015 Nov; 13(11):2076-86. PubMed ID: 26340319
[TBL] [Abstract][Full Text] [Related]
3. TAFI deficiency promotes liver damage in murine models of liver failure through defective down-regulation of hepatic inflammation.
Hugenholtz GC; Meijers JC; Adelmeijer J; Porte RJ; Lisman T
Thromb Haemost; 2013 May; 109(5):948-55. PubMed ID: 23467679
[TBL] [Abstract][Full Text] [Related]
4. Carboxypeptidase B2 deficiency reveals opposite effects of complement C3a and C5a in a murine polymicrobial sepsis model.
Shao Z; Nishimura T; Leung LL; Morser J
J Thromb Haemost; 2015 Jun; 13(6):1090-102. PubMed ID: 25851247
[TBL] [Abstract][Full Text] [Related]
5. Thrombin-activatable fibrinolysis inhibitor protects against acute lung injury by inhibiting the complement system.
Naito M; Taguchi O; Kobayashi T; Takagi T; D'Alessandro-Gabazza CN; Matsushima Y; Boveda-Ruiz D; Gil-Bernabe P; Matsumoto T; Chelakkot-Govindalayathil AL; Toda M; Yasukawa A; Hataji O; Morser J; Takei Y; Gabazza EC
Am J Respir Cell Mol Biol; 2013 Oct; 49(4):646-53. PubMed ID: 23721130
[TBL] [Abstract][Full Text] [Related]
6. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life.
Nagashima M; Yin ZF; Zhao L; White K; Zhu Y; Lasky N; Halks-Miller M; Broze GJ; Fay WP; Morser J
J Clin Invest; 2002 Jan; 109(1):101-10. PubMed ID: 11781355
[TBL] [Abstract][Full Text] [Related]
7. Pulmonary hypertension is ameliorated in mice deficient in thrombin-activatable fibrinolysis inhibitor.
Qin L; D'Alessandro-Gabazza CN; Aoki S; Gil-Bernabe P; Yano Y; Takagi T; Boveda-Ruiz D; Ramirez Marmol AY; San Martin Montenegro VT; Toda M; Miyake Y; Taguchi O; Takei Y; Morser J; Gabazza EC
J Thromb Haemost; 2010 Apr; 8(4):808-16. PubMed ID: 20088932
[TBL] [Abstract][Full Text] [Related]
8. Thrombin-thrombomodulin connects coagulation and fibrinolysis: more than an in vitro phenomenon.
Binette TM; Taylor FB; Peer G; Bajzar L
Blood; 2007 Nov; 110(9):3168-75. PubMed ID: 17644733
[TBL] [Abstract][Full Text] [Related]
9. Demonstration of enhanced endogenous fibrinolysis in thrombin activatable fibrinolysis inhibitor-deficient mice.
Mao SS; Holahan MA; Bailey C; Wu G; Colussi D; Carroll SS; Cook JJ
Blood Coagul Fibrinolysis; 2005 Sep; 16(6):407-15. PubMed ID: 16093731
[TBL] [Abstract][Full Text] [Related]
10. Role of thrombin-activatable fibrinolysis inhibitor in allergic bronchial asthma.
Fujiwara A; Taguchi O; Takagi T; D'Alessandro-Gabazza CN; Boveda-Ruiz D; Toda M; Yasukawa A; Matsushima Y; Miyake Y; Kobayashi H; Kobayashi T; Gil-Bernabe P; Naito M; Yoshida M; Morser J; Takei Y; Gabazza EC
Lung; 2012 Apr; 190(2):189-98. PubMed ID: 22037793
[TBL] [Abstract][Full Text] [Related]
11. Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis.
Wang X; Smith PL; Hsu MY; Tamasi JA; Bird E; Schumacher WA
J Thromb Thrombolysis; 2007 Feb; 23(1):41-9. PubMed ID: 17111204
[TBL] [Abstract][Full Text] [Related]
12. Thrombin activatable fibrinolysis inhibitor (TAFI) at the interface between coagulation and fibrinolysis.
Bouma BN; Mosnier LO
Pathophysiol Haemost Thromb; 2003 Sep-2004 Dec; 33(5-6):375-81. PubMed ID: 15692247
[TBL] [Abstract][Full Text] [Related]
13. Characterization of thrombin activatable fibrinolysis inhibitor in normal and acquired haemostatic dysfunction.
Toh CH
Blood Coagul Fibrinolysis; 2003 Jun; 14 Suppl 1():S69-71. PubMed ID: 14567541
[TBL] [Abstract][Full Text] [Related]
14. Structure-function relationships in thrombin-activatable fibrinolysis inhibitor.
Plug T; Meijers JC
J Thromb Haemost; 2016 Apr; 14(4):633-44. PubMed ID: 26786060
[TBL] [Abstract][Full Text] [Related]
15. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation.
Myles T; Nishimura T; Yun TH; Nagashima M; Morser J; Patterson AJ; Pearl RG; Leung LL
J Biol Chem; 2003 Dec; 278(51):51059-67. PubMed ID: 14525995
[TBL] [Abstract][Full Text] [Related]
16. A novel function of thrombin-activatable fibrinolysis inhibitor during rat liver regeneration and in growth-promoted hepatocytes in primary culture.
Okumura N; Koh T; Hasebe Y; Seki T; Ariga T
J Biol Chem; 2009 Jun; 284(24):16553-16561. PubMed ID: 19386599
[TBL] [Abstract][Full Text] [Related]
17. Thrombin activatable fibrinolysis inhibitor (TAFI) - A possible link between coagulation and complement activation in the antiphospholipid syndrome (APS).
Grosso G; Vikerfors A; Woodhams B; Adam M; Bremme K; Holmström M; Ågren A; Eelde A; Bruzelius M; Svenungsson E; Antovic A
Thromb Res; 2017 Oct; 158():168-173. PubMed ID: 28669410
[TBL] [Abstract][Full Text] [Related]
18. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice.
Nagashima M; Yin ZF; Broze GJ; Morser J
Front Biosci; 2002 Feb; 7():d556-68. PubMed ID: 11815293
[TBL] [Abstract][Full Text] [Related]
19. A low TAFI activity and insufficient activation of fibrinolysis by both plasmin and neutrophil elastase promote organ dysfunction in disseminated intravascular coagulation associated with sepsis.
Hayakawa M; Sawamura A; Gando S; Jesmin S; Naito S; Ieko M
Thromb Res; 2012 Dec; 130(6):906-13. PubMed ID: 22353215
[TBL] [Abstract][Full Text] [Related]
20. Activated TAFI Promotes the Development of Chronic Thromboembolic Pulmonary Hypertension: A Possible Novel Therapeutic Target.
Satoh T; Satoh K; Yaoita N; Kikuchi N; Omura J; Kurosawa R; Numano K; Al-Mamun E; Siddique MA; Sunamura S; Nogi M; Suzuki K; Miyata S; Morser J; Shimokawa H
Circ Res; 2017 Apr; 120(8):1246-1262. PubMed ID: 28289017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
